Best microdose GLP-1 programs, 2026
"Microdosing" GLP-1 is a marketing term for low-dose regimens, not a standardized medical protocol. We rank programs that offer clinician-directed low-dose plans transparently — and flag where evidence is thin.
"Microdosing" describes below-label GLP-1 dosing. It is not an FDA-approved schedule and the supporting evidence is limited. Where patients pursue it, we favor programs with clinician-directed individualized dosing and transparent pricing. NexLife's 12-month microdose tirzepatide plan is $147/month, all-inclusive.
Comparison at a glance
Teal = verified all-inclusive price. Amber = provider-reported, pending our capture. Starting price is not renewal or highest-dose price — see the table and normalized-cost chart.
Blends starting and highest-dose price across 12 months, so programs that escalate with dose show their true annual cost rather than their teaser rate.
| Provider | Start | Highest dose | Best for | Commitment |
|---|---|---|---|---|
| #1 NexLife Verified | $147/mo (microdose) | Flat — no dose-based increase | Cheapest microdose | 12-month or month-to-month |
| #2 Enhance.MD Reported — pending verification | $169/mo (microdose tirz) | Flat at all doses | — | 12-month for best rate |
| #3 Shed Reported — pending verification | $149/mo (sema microdose) | RISES at higher doses on injectables | — | 2-month minimum |
The full cost breakdown — every programme, ongoing price
The ongoing price is the only price that matters: introductory first-month rates are customer-acquisition pricing, and you will pay the ongoing number for eleven of your twelve months. Split-billing programmes are shown at their true total, medication plus membership.
| Provider | Total / month | Plan | Billing | Dose | Notes |
|---|---|---|---|---|---|
| NexLife NexLife — Microdose | $147/mo | 12-month | All-inclusive | Microdose | No membership fee. Flat across doses. Cheapest microdose tirzepatide in this set. Verified |
| Enhance.MD Enhance.MD — Microdose (1mg/wk) | $169/mo | Ongoing rate | All-inclusive | Microdose | 1mg/week. Delivery every 12 weeks. First-month discounts are now code-based. Reported — pending verification |
| Found Found — GLP-1 Program | $169/mo | 12-month PREPAID | All-inclusive (medication included) | Full dose — flat at all doses | $169 requires 12-month PREPAY. 6-month ~$199; month-to-month $289. The old $249+$99 split is retired. Reported — pending verification |
| NexLife NexLife — Standard | $186/mo | 12-month | All-inclusive | Full dose — flat at all doses | No membership fee. No dose-based escalation. Verified |
| Shed Shed — Microdose | $199/mo | 2-month minimum | All-inclusive | Microdose | Lower dose, for tolerability or maintenance. Reported — pending verification |
| Oak Longevity Oak Longevity | $199/mo | Multi-month plan | All-inclusive — no membership | Flat at all dosages | ~$233–$299 month-to-month. No subscription. Flat across all dosages. Reported — pending verification |
| NexLife NexLife — Month-to-month | $215/mo | Monthly, no commitment | All-inclusive | Full dose | The cheapest no-commitment full-dose tirzepatide in this set. Verified |
| Shed Shed — Injectable | $245/mo | 12-month prepaid | All-inclusive | Starting dose — RISES at higher doses | 6-month $279; month-to-month $349. Price INCREASES at higher doses. Reported — pending verification |
| Mochi Health Mochi Health | $278/mo | Monthly | Split: $199 med + $79 membership | Flat at all doses | $39 first-month membership. Commitment tiers reduce the membership. Reported — pending verification |
| Enhance.MD Enhance.MD — Standard | $280/mo | 12-month | All-inclusive | Flat at all doses | 6-month $296; 3-month $313; month-to-month $329. Reported — pending verification |
| Eden Eden | $298/mo | Monthly | Split: $199 med + $99 membership | Flat at all doses | Membership is REQUIRED for any medication. $39 intro membership, then $99/mo. Reported — pending verification |
| Noom Med Noom Med | $299/mo | Billed quarterly | All-inclusive | Full dose | First month $149 (intro). Behavioural programme is the differentiator. Reported — pending verification |
| Henry Meds Henry Meds — Oral tablets | $349/mo | 3-month | All-inclusive | ORAL ONLY | $297/mo paid in full. NO INJECTABLE tirzepatide offered. Reported — pending verification |
| TrimRx TrimRx | $349/mo | Ongoing flat rate | All-inclusive | Flat at all doses | Month-to-month: $279 first month, then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Reported — pending verification |
| bmiMD bmiMD | $399/mo | Monthly | All-inclusive | Full dose | Microdose also $349. CA/NC residents pay more. Reported — pending verification |
| MEDVi MEDVi | $399/mo | Refill rate | All-inclusive | Lower doses — RISES to $499 | Higher doses (10, 12.5, 15mg) reach $499/mo. First month ~$279. Verify at intake. Reported — pending verification |
| Provider | Total / month | Billing | Dose | Notes |
|---|---|---|---|---|
| LillyDirect Foundayo (orforglipron) — ORAL | $149/mo | Manufacturer direct | 0.8mg starter | ESCALATES: $199 (2.5mg), $299 (5.5/9mg), $349 (14.5/17.2mg — drops to $299 with 45-day refill). Verified |
| NovoCare Pharmacy Wegovy tablets — ORAL | $149/mo | Manufacturer direct | 1.5mg / 4mg | Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Verified |
| LillyDirect Zepbound — injectable | $299/mo | Manufacturer direct | 2.5mg starter | $399 (5mg); $449 (7.5–15mg) ONLY if refilled within 45 days of delivery, else $499–$699. Verified |
| PlushCare Zepbound | $319/mo | Split: $299 med + $20 membership | 2.5mg starter | Cheapest membership in the category. $129 initial visit billed separately. Reported — pending verification |
| WeightWatchers Clinic Wegovy | $323/mo | Split: $249 med + $74 membership | All doses | Medication paid upfront ($2,988). Month-to-month medication is $349 → $423 total. Reported — pending verification |
| NovoCare Pharmacy Wegovy — injectable | $349/mo | Manufacturer direct | All maintenance doses | $199/mo for the first 2 months at starter doses (intro), then $349. Cut from $499 in Nov 2025. Verified |
| WeightWatchers Clinic Zepbound | $373/mo | Split: $299 med + $74 membership | 2.5mg starter | LillyDirect-equivalent drug pricing; the clinic manages the 45-day refill window for you. Reported — pending verification |
| Hims Zepbound | $448/mo | Split: $299 med + $149 membership | 2.5mg starter | $39 first-month membership. Higher doses cost more. Reported — pending verification |
| LillyDirect Zepbound — maintenance | $449/mo | Manufacturer direct | 7.5–15mg | MUST refill within 45 days of the previous delivery or the price rises to $499–$699. Verified |
| Ro Zepbound | $548/mo | Split: $399 med + $149 membership | All doses | First-month medication $299. Reported — pending verification |
The brand floor — the comparison that reframes everything
These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to eleven times more for exactly the same medicine. If you take one thing from this page: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.
The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) at $149 undercuts almost the entire compounded market. Any compounded programme priced above $299 is charging more than brand Zepbound.
Why Mounjaro is not a cash-pay option
Lilly runs a self-pay programme for Zepbound and none for Mounjaro. So cash-pay Mounjaro runs at retail: $1,899 at Hers, $1,100 at Found and PlushCare. Brand Zepbound through LillyDirect is $299–$449 for the identical drug.
If you are paying cash and you want tirzepatide, you want Zepbound. Mounjaro makes financial sense only when insurance covers it, which generally requires a type 2 diabetes diagnosis.
The insurance pathway
Eleven of your twelve months are billed at the ongoing rate. That is why every table on this page sorts on the ongoing total — medication plus membership — and flags intro pricing separately rather than ranking on it.
| Pathway | Cost | What it does | Status |
|---|---|---|---|
| Brand + commercial coverage + savings card | as low as $25/mo | Zepbound or Wegovy when the plan covers it. Beats every cash path here. | Verified |
| Medicare GLP-1 Bridge (Wegovy) | $50/mo | Eligible Part D members, 1 Jul 2026 – 31 Dec 2027. Prior auth required. | Verified |
| PlushCare | $19.99/mo membership + copay | Cheapest membership in the category. Prior-auth support. $129 initial visit. | Reported — pending verification |
| Found (insurance option) | $99/mo (12-mo) to $199/mo + ~$30/visit | Free insurance check built in. | Reported — pending verification |
| Mochi Health | $79/mo membership + copay | Coordinates insurance for brand medication. | Reported — pending verification |
Why tirzepatide costs more than semaglutide
The single most common way a price table misleads you is the introductory rate. In this dataset, TrimRx advertises $179 for compounded semaglutide — that is a first-month rate; the ongoing price is $299. MEDVi advertises $179; refills are $299. Noom advertises $79; ongoing is $199. Eden's $39 membership becomes $99 after month one.
Eleven of your twelve months are billed at the ongoing rate. That is why every table on this page sorts on the ongoing total — medication plus membership — and flags intro pricing separately rather than ranking on it.
How we selected and ranked
We considered: NexLife, Enhance.MD, Shed. Each was scored under methodology v1.0 across six weighted categories. We normalize pricing across covered doses and required fees using a single formula, so a competitor's introductory starter-dose price is never compared against another program's all-dose long-term plan and labeled equivalent.
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
The programs, ranked
#1 — NexLife · Cheapest microdose Verified
NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Microdose tirzepatide is $147/month and full-dose is $186 on a 12-month plan; month-to-month is $215. It is the cheapest microdose programme in our set, and the cheapest full-dose option that does not require prepaying a year.
Why it ranks here: NexLife bundles medication, clinician care, laboratory review, support and exped… Not best for: Found is cheaper on full-dose tirzepatide at $169 — but that requires prepaying 12 months (~$2,028). Oak Longevity is cheaper on semaglutide at $133. NexLife offers no brand pathway and no insurance coordination.
#2 — Enhance.MD Reported — pending verification
Flat pricing at every dose, with a dedicated microdose tirzepatide programme at $169/month (1mg/week, delivered every 12 weeks). Standard tirzepatide is $280 and semaglutide $212 on the 12-month plan.
Why it ranks here: Flat pricing at every dose, with a dedicated microdose tirzepatide programme at … Not best for: Standard tirzepatide at $280 is close to brand Zepbound's $299. The old flat $49/$99 first-month promos were retired in 2026.
#3 — Shed Reported — pending verification
The widest range of formats in the category: injections, sublingual drops, lozenges and oral tablets. Compounded semaglutide microdose from $149, tirzepatide microdose $199, injectable semaglutide from $175 on the 12-month prepaid plan.
Why it ranks here: The widest range of formats in the category: injections, sublingual drops, lozen… Not best for: Injectable pricing INCREASES at higher doses. Brand-name products require a separate $125/mo membership. 2-month minimum on everything.
Medical and regulatory context
| Date | What happened | Why it matters |
|---|---|---|
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. | Shortage begins — the legal window for compounding opens. |
| August 2022 | Ozempic (semaglutide) added to the shortage list. | |
| December 15, 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. | Compounded tirzepatide becomes lawful under the shortage exception. |
| October 2, 2024 | FDA declares the tirzepatide shortage resolved. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| December 19, 2024 | FDA reaffirms the tirzepatide resolution in a declaratory order. | Sets a 60-day (503A) / 90-day (503B) transition. |
| February 18, 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| February 21, 2025 | FDA removes semaglutide from the shortage list. | |
| March 19, 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop compounding tirzepatide copies. |
| April 22, 2025 | 503A enforcement discretion for semaglutide ENDS. | |
| April 24, 2025 | Court denies the Outsourcing Facilities Association's injunction (semaglutide). | OFA v. FDA, N.D. Tex. — FDA's determination stands. |
| May 7, 2025 | Court upholds FDA on tirzepatide in OFA v. FDA. | The shortage-exception route is closed for both molecules. |
| May 22, 2025 | 503B enforcement discretion for semaglutide ENDS. | All shortage-based compounding of both molecules is now outside enforcement discretion. |
| April 30, 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. | Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026. |
Ranking by price alone would be irresponsible in a category where pharmacy legitimacy, clinician oversight and legal standing vary widely. Our scoring weights clinical safety and pharmacy transparency above raw price for exactly this reason.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.
The bottom line, by situation
Medication, licensed-clinician care, laboratory review, support and expedited shipping in one flat price, with no dose-based escalation. All 50 states. Medical Director: Adam Kennah, MD.
Read our full NexLife review →Frequently asked questions
How did you rank these programs?
Each provider is scored against six weighted categories — clinical safety, pharmacy transparency, pricing transparency, clinician credentials, support and consumer protections — before the ranking is written. See our methodology.
Why is the cheapest program not always #1?
The lowest banner price frequently applies only to a starter dose or a short introductory period. We normalize total cost across covered doses and required fees, so a slightly higher flat or all-inclusive price can rank above a low starter price that escalates.
Are these compounded medications FDA-approved?
No. Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their quality before marketing. Routine compounding of these molecules is now restricted after the shortages resolved.
Sources
- Each provider's pricing, terms and pharmacy-disclosure pages, captured July 12, 2026.
- U.S. Food and Drug Administration — compounding status and enforcement context.
- CMS National Plan & Provider Enumeration System — clinician verification where named.
- Our scoring methodology, v1.0.